Long ‐Term Optimization of Outcomes With Flexible Adalimumab Dosing in Patients With Moderate to Severe Plaque Psoriasis

ConclusionOptimizing therapy by temporarily increasing the dosing of adalimumab to EW in patients with psoriasis and an inadequate response to adalimumab 40 mg EOW permitted the achievement and long‐term maintenance of clinical improvement.This article is protected by copyright. All rights reserved.

Source: Journal of the European Academy of Dermatology and Venereology - March 10, 2018 Category: Dermatology Authors: R. Gniadecki, C. L. Leonardi, K. B. Gordon, H. D. Teixeira, Z. Geng, A. Nader, Y. Gu Tags: Original Article Source Type: research